Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy

Next Previous
Trial Profile

Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Actinium 225 DOTATATE (Primary) ; Everolimus; Lanreotide; Octreotide; Sunitinib
  • Indications Gastro-enteropancreatic neuroendocrine tumour
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ACTION-1
  • Sponsors RayzeBio

Most Recent Events

  • 30 Mar 2026 Planned number of patients changed from 388 to 338.
  • 23 Mar 2026 Planned number of patients changed from 288 to 388.
  • 23 Mar 2026 Planned End Date changed from 1 Dec 2026 to 1 Dec 2030.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top